Old Articles: <Older 8241-8250 Newer> |
|
The Motley Fool January 18, 2012 Sean Williams |
This Company is Quickly Approaching the Patent Cliff Earnings exceed expectations at drug manufacturer Forest Laboratories, but worries about future sales mount. |
The Motley Fool January 18, 2012 Sean Williams |
Are These 2 Medical Device Makers Takeover Targets? Could these two medical device makers put themselves up for sale in 2012? |
The Motley Fool January 18, 2012 |
What Johnson & Johnson Does With Its Cash Over the last five years, Johnson & Johnson shares returned 14%, which drops to -3% without dividends -- not a bad boost to top off otherwise lowly share performance. |
The Motley Fool January 18, 2012 Dan Caplinger |
Has St. Jude Medical Become the Perfect Stock? St. Jude took a big step toward perfection when it initiated a big dividend in early 2011. |
The Motley Fool January 17, 2012 Brian Orelli |
You Can Forget About Seeing This Drug Work Medivation and Pfizer's Dimebon fails again. |
The Motley Fool January 17, 2012 Brian Orelli |
Pharma Focus Is Good For Your Portfolio Build your own portfolio. |
The Motley Fool January 17, 2012 Dan Caplinger |
What 2012 Has in Store for Star Scientific Let's look at this year's prospects for this company. |
The Motley Fool January 15, 2012 Brian Orelli |
3 Lessons From the J.P. Morgan Health-Care Confab After 30 years, the conference still offers useful takeaways. This years: Some biotechs never die... In the United States, more people die from flu each year than die from HIV AIDS... Drug launches are back (maybe)... |
The Motley Fool January 13, 2012 Sean Williams |
CEO Gaffe of the Week: Bristol-Myers Squibb Some days, CEOs would be better off staying in bed. |
The Motley Fool January 13, 2012 Dan Caplinger |
Has Intuitive Surgical Become the Perfect Stock? What Intuitive Surgical needs to do to get even closer to perfection is to get to the point in its growth curve at which it's ready to start paying dividends. |
<Older 8241-8250 Newer> Return to current articles. |